Although association data preclude the establishment of any causal effect between plasma FABP4 levels and liver triglyceride composition, our findings strongly support the role of circulating FABP4 as a potential biomarker of NAFLD. This evidence concerns the gene FABP4 and metabolic dysfunction-associated steatotic liver disease.